Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Non-Current Assets (2022 - 2025)

Historic Other Non-Current Assets for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $2.9 million.

  • Phathom Pharmaceuticals' Other Non-Current Assets changed 0.0% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $2.9 million for FY2024, which is 3.49% down from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Other Non-Current Assets stood at $2.9 million, which was down 0.0% from $2.9 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Other Non-Current Assets high stood at $3.8 million for Q3 2023, and its period low was $505000.0 during Q4 2022.
  • Moreover, its 4-year median value for Other Non-Current Assets was $2.9 million (2024), whereas its average is $2.3 million.
  • As far as peak fluctuations go, Phathom Pharmaceuticals' Other Non-Current Assets crashed by 3726.71% in 2023, and later skyrocketed by 46772.28% in 2024.
  • Over the past 4 years, Phathom Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $505000.0 in 2022, then skyrocketed by 466.93% to $2.9 million in 2023, then decreased by 0.03% to $2.9 million in 2024, then changed by 0.0% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $2.9 million for Q2 2025, and $2.9 million during Q1 2025.